Managing FGFRi AEs
Managing Toxicities Associated With FGFR Inhibitors in Urothelial Cancer and Beyond

Released: May 04, 2021

Expiration: May 03, 2022

Alison Birtle
Alison Birtle, MD, FRCP, FRCR
Ignacio Duran
Ignacio Duran, MD, PhD

Activity

Progress
1
Course Completed

In this episode, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss toxicities associated with FGFR inhibitors used in the treatment of urothelial cancer and other malignancies.   

Presenters:

Ignacio Durán, MD, PhD
Associate Professor
GU Oncology Program Leader
Department of Medical Oncology
Hospital Universitario Marques de Valdecilla-Idival
Santander, Spain

Alison Birtle, MD, FRCP, FRCR
Honorary Senior Lecturer
Faculty of Health and Medicine
University of Manchester
Manchester, United Kingdom
Consultant Oncologist
Rosemere Cancer Centre
Lancashire Teaching Hospitals
Preston, Lancashire, United Kingdom